Esperion Therapeutics ESPR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$25.2M— | —— | -$31.33M-146% | -$12.73M+68.5% | -$40.46M-89.8% | ||
| $27K+3.8% | $26K0.0% | $26K-3.7% | $27K+3.8% | $26K-3.7% | ||
| $2.5M+4.8% | $2.39M+1.6% | $2.35M-12.0% | $2.67M+8.3% | $2.47M-12.1% | ||
| $589K-8.1% | $641K-24.3% | $847K+3.3% | $820K+17.3% | $699K+306% | ||
| -$7.84M-137% | $21.21M+88.8% | $11.23M-57.5% | $26.45M+2,196% | $1.15M-90.6% | ||
| -$915K— | —— | —— | $15.14M+213% | $4.83M-66.4% | ||
| $3.34M— | —— | $2.9M+10.8% | $2.62M-90.6% | $27.84M+199% | ||
| -$4.86M-138% | $12.72M-40.0% | $21.18M+1,312% | -$1.75M-87.6% | -$932K-115% | ||
| $17.34M+94.7% | $8.91M+44.2% | $6.18M-42.8% | $10.79M+119% | $4.93M+33.4% | ||
| $9.05M+138% | $3.8M-54.6% | $8.37M-52.9% | $17.77M+547% | -$3.98M+39.4% | ||
| -$27.72M— | —— | -$4.29M+86.4% | -$31.42M-38.9% | -$22.63M+35.3% | ||
| $189K— | $0— | $0— | $0— | $0— | ||
| -$189K— | $0— | $0— | $0— | $0— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| —— | $61K0.0% | $61K0.0% | $61K0.0% | $61K+741% | ||
| $16.22M-46.2% | $30.16M+183% | $10.67M+274% | $2.85M+138% | -$7.5M-121% | ||
| -$11.69M-116% | $75.41M+1,081% | $6.39M+122% | -$28.57M+5.2% | -$30.13M-68,573% | ||
| —— | $4.07M0.0% | $4.07M0.0% | $4.07M0.0% | $4.07M+43.4% | ||
| —— | $153K0.0% | $153K0.0% | $153K0.0% | $153K— | ||
| $589K-8.1% | $641K-24.3% | $847K+3.3% | $820K+17.3% | $699K+306% | ||
| $27K+3.8% | $26K0.0% | $26K-3.7% | $27K+3.8% | $26K-3.7% | ||
| $9.05M— | —— | —— | —— | -$3.98M— | ||
| -$4.86M-138% | $12.72M-40.0% | $21.18M+1,312% | -$1.75M-87.6% | -$932K-115% | ||
| $17.34M+94.7% | $8.91M+44.2% | $6.18M-42.8% | $10.79M+119% | $4.93M+33.4% | ||
| $13.89M-14.3% | $16.21M+10.8% | $14.64M+10.3% | $13.27M+1.4% | $13.09M+3.3% | ||
| $18.48M+26.3% | $14.64M-10.5% | $16.36M+20.5% | $13.58M+29.6% | $10.48M+8.2% | ||
| $0— | —— | —— | —— | $7.5M— | ||
| —— | $18.15M0.0% | $18.15M0.0% | $18.15M0.0% | $18.15M-19.9% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| —— | $61K0.0% | $61K0.0% | $61K0.0% | $61K+741% | ||
| $16.22M+56.7% | $10.35M— | $0— | $0— | $0— | ||
| —— | $13.73M0.0% | $13.73M0.0% | $13.73M0.0% | $13.73M-73.9% | ||
| —— | $153K0.0% | $153K0.0% | $153K0.0% | $153K— | ||
| $27K+238% | $8K-11.1% | $9K— | —— | $30K+66.7% | ||
| -$27.91M— | —— | -$4.29M+86.4% | -$31.42M-38.9% | -$22.63M+35.3% | ||
| -$27.91M— | —— | -$4.29M+86.4% | -$31.42M-38.9% | -$22.63M+35.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Esperion Therapeutics generate?
- Esperion Therapeutics (ESPR) generated -$86.1M in operating cash flow over the trailing twelve months.
- What is Esperion Therapeutics's free cash flow?
- After $189.0K of capital expenditures, Esperion Therapeutics's free cash flow was -$86.2M over the trailing twelve months, down 129.5% year over year.
- Where does Esperion Therapeutics's cash flow data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
